Ascendis Pharma A/S Announces Annual General Meeting Notice
Ticker: ASND · Form: 6-K · Filed: Apr 29, 2025 · CIK: 1612042
| Field | Detail |
|---|---|
| Company | Ascendis Pharma A/S (ASND) |
| Form Type | 6-K |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: agm, corporate-governance, filing
Related Tickers: ASND
TL;DR
Ascendis Pharma (ASND) filed a 6-K for its upcoming Annual General Meeting notice.
AI Summary
Ascendis Pharma A/S has filed a Form 6-K on April 29, 2025, to provide a convening notice for its Annual General Meeting. This notice informs the company's shareholders about the upcoming meeting, which is a standard procedural filing for public companies.
Why It Matters
This filing is a routine corporate governance update, informing shareholders about an upcoming meeting where key company decisions are typically discussed and voted upon.
Risk Assessment
Risk Level: low — This filing is a routine administrative notice and does not contain new financial or operational information that would typically impact stock price.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- April 29, 2025 (date) — Filing Date
- Form 6-K (document) — Filing Type
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to furnish Exhibit 99.1, which is the convening notice for the Annual General Meeting of Ascendis Pharma A/S.
When was this Form 6-K filed?
This Form 6-K was filed on April 29, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Ascendis Pharma A/S.
What is the company's principal executive office address?
The company's principal executive office address is Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
Does Ascendis Pharma A/S file annual reports under Form 20-F or 40-F?
Ascendis Pharma A/S files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 29, 2025 regarding Ascendis Pharma A/S (ASND).